CoChat

LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence

Published version of a preprint

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Abstract

Gastrointestinal cancer is one of the leading causes of cancer-related mortality in men and women worldwide. The adult stem cell marker LGR5 (leucine-rich repeat-containing, G protein–coupled receptor 5) is highly expressed in a significant fraction of gastrointestinal tumors of the colon, liver, pancreas, and stomach, relative to normal tissues. LGR5 is located on the cell surface and undergoes rapid, constitutive internalization independent of ligand. Furthermore, LGR5-high cancer cells have been shown to exhibit the properties of tumor-initiating cells or cancer stem cells (CSC). On the basis of these attributes, we generated two LGR5-targeting antibody–drug conjugates (ADC) by tethering the tubulin-inhibiting cytotoxic drug monomethyl auristatin E to a highly specific anti-LGR5 mAb via a protease cleavable or noncleavable chemical linker and compared them in receptor binding, cell internalization, and cytotoxic efficacy in cancer cells. Here, we show that both ADCs bind LGR5 with high specificity and equivalent nanomolar affinity and rapidly internalize to the lysosomes of LGR5-expressing gastrointestinal cancer cells. The anti-LGR5 ADCs effectively induced cytotoxicity in LGR5-high gastrointestinal cancer cells, but not in LGR5-negative or -knockdown cancer cell lines. Overall, we demonstrate that the cleavable ADC exhibited higher potency in vitro and was able to eradicate tumors and prevent recurrence in a xenograft model of colon cancer. These findings provide preclinical evidence for the potential of LGR5-targeting ADCs as effective new therapeutics for the treatment and eradication of gastrointestinal tumors and CSCs with high LGR5 expression. Mol Cancer Ther; 15(7); 1580–90. ©2016 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-16-0114

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Cited by

See all 135

Metadata

Authors
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S.
Affiliations
  • Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
  • The University of Texas Health Science Center at Houston (US)
Venue
Molecular Cancer Therapeutics
Published
2016-07-01
Volume
15
Issue
7
Pages
1580-1590
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2396016364
Cited by
130
References
45
Citations by year
2026: 11 · 2025: 11 · 2024: 13 · 2023: 10 · 2022: 7 · 2021: 29 · 2020: 16 · 2019: 9 · 2018: 13 · 2017: 9 · 2016: 2
FWCI
9.54
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Cancer Prevention Research Institute of Texas (RP150640)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
Keywords
Lgr5, antibody-drug conjugates, gastrointestinal cancer, colon cancer, cancer stem cells, monomethyl auristatin E, tubulin polymerization inhibitors, receptor internalization, lysosomal targeting, cleavable linkers, tumor recurrence prevention, xenograft models
MeSH terms
Animals, Antibodies, Monoclonal, Antineoplastic Agents, Cell Survival, Disease Models, Animal, Female, Gastrointestinal Neoplasms, Humans, Neoplasm Recurrence, Local, Gene Expression, Immunoconjugates, Xenograft Model Antitumor Assays, Receptors, G-Protein-Coupled, Cell Line, Tumor, Tumor Burden, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0114
The paper
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016). LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.